CClinicalTrials.gg
CompletedNCT00147004CorticusUpdated Apr 24, 2008

Corticosteroid Therapy of Septic Shock - Corticus

A Phase 3 interventional study of hydrocortisone sodium succinate and Placebo in Shock, Septic, sponsored by Hadassah Medical Organization. Completed at 57 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-24.

Sponsored by Hadassah Medical Organization · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to determine whether steroids decrease 28-day mortality in patients with septic shock.

Read the detailed description

The use of steroids in septic shock remains controversial. The purpose of this study is to determine whether hydrocortisone decreases 28-day mortality in patients with septic shock. The primary end point will be 28-day mortality in all the non-responders to ACTH (\< or = 9 mcg/dl or 250 nmol/L post ACTH). Secondary endpoints will be 28 day all cause mortality in the total group and in responders, ICU and hospital mortality, one year mortality, organ system failure reversal especially shock, and duration of ICU and total hospitalisation.

In a double-blinded fashion (randomized on a 1:1 basis), patients receive 50 mg intravenously every 6 hours for 5 days. After 5 days, treatment will be tapered with 50 mg given intravenously every 12 hours for days 6-8, then 50 mg every 24 hours for days 9-11, and then stopped.

All concomitant treatments, including antibiotics, fluids, vasopressors and ancillary therapies will be given at the discretion of the primary care physician. Evidence-based guidelines for the management of severe sepsis and septic shock by the International Sepsis Forum (Intensive Care Med 2001;27:S124-S134) are encouraged to be followed.

All serious adverse events (SAE) which occur between days 0 and 28, which are unexpected and/or considered possibly or probably related to the study medication, must be documented and reported within 24 hours to the Safety and Efficacy Monitoring Committee. Non-serious adverse events will be listed on the case report form if they are unexpected and believed to be related to the study drug during days 0 to 14.

Specific adverse events which will be monitored closely because of their relationship to corticosteroids and shock are:

  1. Use of corticosteroids, i.e. gastrointestinal bleeding and superinfection; hyperglycemia, hypernatremia, muscular weakness, etc.
  2. Shock and use of vasopressors, i.e. stroke, acute myocardial infarction and peripheral ischemia.

In addition, substudies will include harmonization of cortisol by comparing cortisol levels measured in local laboratories and a central laboratory, immune and neuro-endocrine interactions, neuromuscular weakness and cytokines.

02

Conditions studied

  • Shock, Septic

Keywords

  • Septic shock
  • Steroids
  • Hydrocortisone
  • Mortality
  • Reversal of shock
  • Adrenal insufficiency
03

In context

Shock, Septic

862 studies on the registry are indexed under Shock, Septic; 207 are open to participants now.

This study's enrollment of 500 is above the median of 80 across 530 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Hadassah Medical Organization is the lead sponsor of 659 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Clinical evidence of infection within the previous 72 hours (may be present longer than 72 hours) (a, b, c, or d - only 1 required)

    1. Presence of polymorphonuclear cells in a normally sterile body fluid (excluding blood);
    2. Culture or Gram stain of blood, sputum, urine or normally sterile body fluid positive for a pathogenic micro-organism;
    3. Focus of infection identified by visual inspection (e.g. ruptured bowel with the presence of free air or bowel contents in the abdomen found at the time of surgery, wound with purulent drainage);
    4. Other clinical evidence of infection - treated community acquired pneumonia, purpura fulminans, necrotising fascitis, etc.
  2. Evidence of a systemic response to infection as defined by the presence of two or more of the following signs within the previous 24 hours. These signs may be present longer than 72 hours.

    1. Fever (temperature >38.3°C) or hypothermia (rectal temperature \< 35.6°C);
    2. Tachycardia (heart rate of >90 beat/min);
    3. Tachypnea (respiratory rate > 20 breaths/min, PaC02\<32 mmHg) or patient requires invasive mechanical ventilation;
    4. Alteration of the WBC count >12,000 cells/mm3, \<4,000 cells/mm3 or >10% immature neutrophils (bands).
  3. Evidence of shock defined by (A + B- both required within the previous 72 hours (may NOT be present longer than 72 hours).

A. A systolic blood pressure \< 90 mmHg or a decrease in SBP of more than 50 mmHg from baseline in previous hypertensive patients (for at least one hour) despite adequate fluid replacement OR need for vasopressors for at least one hour (infusion of dopamine ≥ 5 mcg/kg/min or any dose of adrenaline, noradrenaline, phenylephrine or vasopressin) to maintain a SBP ≥ 90 mmHg;

B. Hypoperfusion or organ dysfunction which is not the result of underlying diseases or drugs, but is attributable to sepsis, including one of the following:

  1. Sustained oliguria (urine output \< 0.5 ml/kg/hr for a minimum of 1 hour)
  2. Metabolic acidosis [pH of \< 7.3, or a base deficit of > or = 5.0 mmol/L, or an increased lactic acid concentration (> 2 mmol/L)].
  3. Arterial hypoxemia (Pa02/FI02\<280 in the absence of pneumonia)(Pa02/FI02\<200 in the presence of pneumonia).
  4. Thrombocytopenia - platelet count ≤ 100,000 cells/mm3.
  5. Acute altered mental status (Glasgow Coma Scale \< 14 or acute change from baseline).
  1. Informed Consent
  1. Cortisol level at baseline and 60 minutes after 0.25 mg cosyntropin

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy
  2. Age less than 18.
  3. Underlying disease with a prognosis for survival of less than 3 months.
  4. Cardiopulmonary resuscitation within 72 hours before study.
  5. Drug-induced immunosuppression, including chemotherapy or radiation therapy within 4 weeks before the study.
  6. Administration of chronic corticosteroids in the last 6 months or acute steroid therapy (any dose) within 4 weeks (including inhaled steroids). Topical steroids are not exclusions.
  7. HIV positivity.
  8. Presence of an advanced directive to withhold or withdraw life sustaining treatment (i.e. DNR).
  9. Advanced cancer with a life expectancy less than 3 months.
  10. Acute myocardial infarction or pulmonary embolus.
  11. Another experimental drug study within the last 30 days.
  12. Moribund patients likely to die within 24 hours.
  13. Patients in the ICU for more than 2 months at the time of the start of septic shock.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (actual)

Study arms

  • Experimental
    1

    hydrocortisone sodium succinate

    Drug: hydrocortisone sodium succinate

  • Placebo comparator
    2

    Placebo

    Drug: Placebo

Interventions

  • Drughydrocortisone sodium succinate

    50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. 28 day mortality in all the non-responders to ACTH (< or = 9 mcg/dl or 250 nmol/L post ACTH)

    Time frame: 28 days

Secondary outcomes

  1. 28 day all cause mortality in the total group.

    Time frame: 28 days

  2. 28 day all cause mortality in responders.

    Time frame: 28 days

  3. One year mortality in nonresponders, total and responders.

    Time frame: one year

  4. ICU and hospital mortality.

    Time frame: one year

  5. Organ system failure reversal, especially shock.

    Time frame: one year

  6. Duration of ICU and total hospitalisation.

    Time frame: one year

07

Study locations

57 sites
  • LKH Feldkirch
    Feldkirch, A-6800, Austria
  • KH-BHS Linz
    Linz, A-4010, Austria
  • Krankenhaus der Barmherzigen Schwestern Ges. mbH
    Linz, A-4010, Austria
  • Universitaetsklinik fuer Innere Medizin II
    Wien, A 1090, Austria
  • Hopital St. Joseph
    Arlon, B-6700, Belgium
  • University Hospital Erasme
    Brussels, B-1070, Belgium
  • Cliniques Universitaires St. Luc, UCL
    Brussels, B-1200, Belgium
  • CHU Charleroi
    Charleroi, B-6000, Belgium
  • Hopital Raymond Poincare
    Paris, Garches F-92380, France
  • Hopital Lariboisiere
    Paris, Oarus F-75010, France
  • Hopital de Caen
    Caen, 14033, France
  • Hopital Huriez
    Lille, F-59037, France
  • Hopital Caremeau
    Nimes, 30029 cedex 9, France
  • Hopital Saint-Antoine
    Paris, F-75571, France
  • Zentralklinikum Augsburg
    Augsburg, D-86155, Germany
  • Vivantes-Klinikum im Friedrichshain
    Berlin, D - 10249, Germany
  • Vivantes-Klinikum Spandau
    Berlin, D - 13585, Germany
  • Evangelisches Waldkrankenhaus Spandau
    Berlin, D - 13589, Germany
  • Charité Campus Mitte
    Berlin, D-10117, Germany
  • St. Joseph Krankenhaus
    Berlin, D-12101, Germany
  • Charité - Campus Benjamin Franklin
    Berlin, D-12200, Germany
  • Vivantes-Klinikum Neukoelln
    Berlin, D-12313, Germany
  • Charité - Campus Charité Mitte
    Berlin, D-13353, Germany
  • Charité Campus Virchow -Klinikum
    Berlin, D-13353, Germany
  • Charité Campus Virchow-Klinikum
    Berlin, D-13353, Germany
  • Charité- Campus Virchow- Klinikum
    Berlin, D-13353, Germany
  • Institute for Anaesthesia and Operative Intensive Care
    Darmstadt, D-64283, Germany
  • University Hospital Dresden
    Dresden, D- 01307, Germany
  • Krankenhaus Hennigsdort
    Hennigsdorf, D-16761, Germany
  • Friedrich-Schiller Universitaet
    Jena, D - 07740, Germany
  • Klinikum Kemptern-Oberallegaeu
    Kempten, D-87439, Germany
  • Klinikum Landshut
    Landshut, D-84034, Germany
  • Klinikum Mannheim, University of Heidelberg
    Mannheim, D- 68167, Germany
  • Staedtisches Krankenhaus Muenchen-Harlaching
    Muenchen, D- 81545, Germany
  • Ludwig-Maximilian-Universitaet Muenchen
    Muenchen, D-81366, Germany
  • Klinikum Grosshadern, LMU Munich
    Munich, D-81377, Germany
  • Univesitaet Erlangen-Namberg
    Nurenberg, D-90471, Germany
  • Klinikum Ernst von Bergman
    Potsdam, D-14467, Germany
  • Haemek Hospital
    Afula, 18101, Israel
  • Hadassah Medical Organisation
    Jerusalem, 91120, Israel
  • Beilinson Medical Centre
    Petach Tikva, 491000, Israel
  • Ichilov Hospital
    Tel Aviv, 64239, Israel
  • Policlinico di Tor Vergata
    Roma, 00133, Italy
  • Centro di Rianimazione Ospedale S.Eugenio
    Roma, 00144, Italy
  • Renier de Graaf Hospital
    Delft, 2600 GA, Netherlands
  • Erasmus University Medical Centre
    Rotterdam, 3000 CA, Netherlands
  • Hospital de St. Antonio do Capuchos
    Lisboa, 1150, Portugal
  • UCIP, Hospital de Desterro
    Lisbon, 1150, Portugal
  • Hospital de Egas Moniz
    Lisbon, 1349-019, Portugal
  • Aberdeen Royal Infirmary
    Aberdeen, AB25 2ZD, United Kingdom
  • Southend Hospital
    Essex, SSO ORY, United Kingdom
  • Ipswich Hospital
    Ipswich, IP4 5PD, United Kingdom
  • Royal Lancaster Infirmary
    Lancaster, LA1 4RP, United Kingdom
  • The General Infirmary at Leeds
    Leeds, LS1 3EX, United Kingdom
  • Bloomsbury Institute of Intensive Care Medicine
    London, W1T 3AA, United Kingdom
  • University of Manchester, Hope Hospital
    Salford, M6 8HD, United Kingdom
  • Southampton General Hospital
    Southampton, United Kingdom
08

References and documents

Publications

  • Annane D, Briegel J, Sprung CL. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 May 22;348(21):2157-9. doi: 10.1056/NEJM200305223482123. No abstract available. PubMed 12761380 ↗
  • Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008 Jan 10;358(2):111-24. doi: 10.1056/NEJMoa071366. PubMed 18184957 ↗
  • Polito A, Sonneville R, Guidoux C, Barrett L, Viltart O, Mattot V, Siami S, Lorin de la Grandmaison G, Chretien F, Singer M, Gray F, Annane D, Brouland JP, Sharshar T. Changes in CRH and ACTH synthesis during experimental and human septic shock. PLoS One. 2011;6(11):e25905. doi: 10.1371/journal.pone.0025905. Epub 2011 Nov 3. PubMed 22073145 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00147004
Lead sponsor
Hadassah Medical Organization
Collaborators
European Society of Intensive Care Medicine, International Sepsis Forum, The Gorham Foundation
First posted
Sep 7, 2005
Start date
Mar 2002
Primary completion
Nov 2005
Completion
Nov 2005
Last update
Apr 24, 2008

Study contacts

Charles L Sprung, MD
study chair · Hadasah Medical Organization
Djillali Annane, MD
study director · Hopital Raymond Poincare
Josef Briegel, MD
study director · Ludwig-Maximilian-Universitaet Muenchen
Didier Keh, MD
study director · Charite Campus Virchow-Klinikum
Rui Moreno, MD
study director · Hospital de St. António dos Capuchos
Didier Pittet, MD
study director · University Hospital, Geneva
Mervyn Singer, MD
study director · University College, London

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion